Fagron NV 2021 AR2
The report highlights Fagron's performance in 2021, achieving a turnover growth of 3.2% to 573.8 million euros despite the ongoing challenges of the COVID-19 pandemic. The company made significant progress in its ESG strategy, reducing its greenhouse gas intensity by 20.4% compared to 2019. Key operational milestones included the commissioning of a new repackaging facility in Poland and a sterile compounding facility in Israel. Additionally, Fagron expanded its portfolio through the acquisition of US Compounding assets in North America and HeW Pharma in Belgium.
Company: Fagron NV
Sector: Health Care
Country: Belgium
Year: 2021
Type: AR2
Pages: 118
Fagron NV
Annual Report
The report highlights Fagron's performance in 2021, achieving a turnover growth of 3.2% to 573.8 million euros despite the ongoing challenges of the COVID-19 pandemic. The company made significant progress in its ESG strategy, reducing its greenhouse gas intensity by 20.4% compared to 2019. Key operational milestones included the commissioning of a new repackaging facility in Poland and a sterile compounding facility in Israel. Additionally, Fagron expanded its portfolio through the acquisition of US Compounding assets in North America and HeW Pharma in Belgium.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees